InvestSMART

Nexsen Limited (ASX:NXN)

ALERT: Price-sensitive ASX Announcement for NXN
Current share price for NXN : $0.240 -0.03 (-11.11%)+
Announcement
Release
29 Jul 2026 8:33AM
Price at Release
$0.270
Full Release
download
Summary
Nexsen Limited's Quarterly Activities Report for Q4 FY26 highlights significant progress in their Asia-Pacific strategy, focusing on hospital access, healthcare leadership, and manufacturing readiness. The company has signed a term sheet with Gleneagles Hospital in Hong Kong, expanding their diagnostic devices into a leading clinical environment. This partnership is poised to facilitate clinical validation and potential adoption across North Asia. Additionally, Nexsen has strengthened its leadership by adding Dr. Kenneth Tsang to its Advisory Board, leveraging his experience from IHH Healthcare. The report also notes the launch of a Malaysian research facility with Universiti Malaya, which enhances their R&D capabilities. Financially, the company ended the quarter with $4.49 million in cash reserves and demonstrated consistent expenditure alignment with their Prospectus, despite some accelerated spending on the GBS Rapid Sensor project. Overall, Nexsen is well-positioned for future commercial manufacturing and global expansion.
Key Points
  • Significant advance in Asia-Pacific strategy.
  • Partnership with Gleneagles Hospital Hong Kong.
  • Appointment of Dr. Kenneth Tsang to Advisory Board.
  • Launch of Malaysian research facility with Universiti Malaya.
  • Ended quarter with $4.49 million in cash reserves.
  • Consistent expenditure with IPO Prospectus, with some accelerations.
  • More than $1.5 million in additional non-dilutive funding secured.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.